SEC Form 4	
FORM 4	U

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

I	OMB Number:	DMB Number: 3235-0287							
	Estimated average burden								
	hours per response:	0.5							

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Roberts Christopher D.			Black Diamond Therapeutics, Inc. [BDTX]		Director	10% Owner					
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC.		ERAPEUTICS, INC.	3. Date of Earliest Transaction (Month/Day/Year) 01/04/2021	X	Officer (give title below) Chief Scientific	Other (specify below) c Officer					
ONE MAIN STREET, 10TH FLOOR			4. If Amendment, Date of Original Filed (Month/Day/Year)		Individual or Joint/Group Filing (Check Applicable						
(Street) CAMBRIDGE	MA	02142		Line)	Form filed by One Rep Form filed by More that Person	Ū.					
(City)	(State)	(Zip)									
		Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	01/04/2021		М		2,500	A	\$10.86	5,700	D	
Common Stock	01/04/2021		S ⁽¹⁾		1,963	D	\$ 31.3093 ⁽²⁾	3,737	D	
Common Stock	01/04/2021		S ⁽¹⁾		537	D	\$ 31.7775 ⁽³⁾	3,200	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$10.86	01/04/2021		М			2,500	(4)	09/08/2029	Common Stock	2,500	\$0.00	173,609	D	

Explanation of Responses:

1. Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$30.72 to \$31.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.72 to \$32.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Assert any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
So of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Brent Hatzis-Schoch, as

Attorney-in-Fact

01/06/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.